These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28799501)

  • 1. EDITORIAL: Advances in Developing Versatile Tools for the Discovery of Novel Therapeutics.
    Hu Y
    Curr Top Med Chem; 2017; 17(20):2233-2234. PubMed ID: 28799501
    [No Abstract]   [Full Text] [Related]  

  • 2. Advancing the kinase field: new targets and second generation inhibitors.
    Laufer S; Bajorath J
    J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
    [No Abstract]   [Full Text] [Related]  

  • 3. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
    Alsfouk A
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
    Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
    Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemistry and Chemical Biology of Therapeutically Important Compounds.
    Disney MD
    Bioorg Med Chem; 2016 Sep; 24(17):3875. PubMed ID: 27460698
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy.
    Wang YT; Jiang SQ; Zhang SL
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38998978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of aurora kinase inhibitors as anticancer agents.
    Pollard JR; Mortimore M
    J Med Chem; 2009 May; 52(9):2629-51. PubMed ID: 19320489
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial:Shaping Current and Future Kinase Drug Discovery.
    Bhalla N
    Curr Top Med Chem; 2017; 17(22):2469. PubMed ID: 28799507
    [No Abstract]   [Full Text] [Related]  

  • 9. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
    Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB
    J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
    Jin M; Wang J; Buck E; Mulvihill MJ
    Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions.
    Cerchia C; Lavecchia A
    Curr Med Chem; 2017; 24(21):2312-2344. PubMed ID: 28413965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in small-molecule drug discovery for triple-negative breast cancer.
    Fosu-Mensah N; Peris MS; Weeks HP; Cai J; Westwell AD
    Future Med Chem; 2015; 7(15):2019-39. PubMed ID: 26495746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When will small molecule lactate dehydrogenase inhibitors realize their potential in the cancer clinic?
    Rani R; Kumar V
    Future Med Chem; 2017 Jul; 9(11):1113-1115. PubMed ID: 28722474
    [No Abstract]   [Full Text] [Related]  

  • 14. [Research progress of the small molecule covalent inhibitors].
    Yang B; Wang WJ; Li LL
    Yao Xue Xue Bao; 2014 Feb; 49(2):158-65. PubMed ID: 24761604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
    Chaudhary D; Robinson S; Romero DL
    J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.
    Lawrence HR; Mahajan K; Luo Y; Zhang D; Tindall N; Huseyin M; Gevariya H; Kazi S; Ozcan S; Mahajan NP; Lawrence NJ
    J Med Chem; 2015 Mar; 58(6):2746-63. PubMed ID: 25699576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
    Mittapalli GK; Jackson A; Zhao F; Lee H; Chow S; McKelvy J; Wong-Staal F; Macdonald JE
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6852-5. PubMed ID: 21978675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics.
    Zheng S; Liu J; Wu Y; Huang TL; Wang G
    Future Med Chem; 2015; 7(18):2485-505. PubMed ID: 26670195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm.
    Fu RG; Sun Y; Sheng WB; Liao DF
    Eur J Med Chem; 2017 Aug; 136():195-211. PubMed ID: 28494256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the tetrahydroquinoline pharmacophore.
    Goli N; Mainkar PS; Kotapalli SS; K T; Ummanni R; Chandrasekhar S
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1714-1720. PubMed ID: 28318941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.